An undisclosed amount of seed funding has been provided by two UK investors for a start-up gene therapy company that is working on a concept for preventing nerve damage in glaucoma, the leading cause of irreversible blindness worldwide. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Finance, Grants, Deals
